• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Molecular Templates Inc.

    2/14/24 8:39:50 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTEM alert in real time by email
    SC 13G 1 mtem-sc13g_123123.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. __)*

     

    Molecular Templates, Inc. 

    (Name of Issuer)

     

    Common Stock 

    (Title of Class of Securities)

     

    608550208 

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☒  Rule 13d-1(b)
    ☐  Rule 13d-1(c)
    ☐  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.608550208 13G Page 2 of 9

     

    1. NAMES OF REPORTING PERSONS

    SilverArc Capital Management, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    354,608
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    354,608
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    354,608
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.60%
    12. TYPE OF REPORTING PERSON (see instructions)

    IA
           

     

     

     

    CUSIP No.608550208 13G Page 3 of 9

     

    1. NAMES OF REPORTING PERSONS

    Devesh Gandhi
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Massachusetts
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    354,608
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    354,608
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    354,608
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.60%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN
           

     

     

     

    CUSIP No.608550208 13G Page 4 of 9

     

    Item 1.

     

    (a)Name of Issuer

     

    Molecular Templates, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    9301 Amberglen Blvd Ste 100, Austin, TX

     

    Item 2.

     

    (a)Name of Person Filing

     

    SilverArc Capital Management, LLC (“SilverArc”) and Devesh Gandhi (“Gandhi” and together with SilverArc, the “Reporting Persons”)

     

    (b)Address of the Principal Office or, if none, residence

     

    20 Park Plaza, 4th Floor

     

    Boston, MA 02116

     

    (c)Citizenship

     

    SilverArc is a Delaware limited liability company. Gandhi is a citizen of the United States.

     

    (d)Title of Class of Securities

     

    Common Stock

     

    (e)CUSIP Number

     

    608550208

     

     

     

     

    CUSIP No.608550208 13G Page 5 of 9

     

    Item 3. If this statement is filed pursuant to Sec. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.D. 78o):

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

    (e)☒ An investment adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E);

    (f)☐ An employee benefit plan or endowment fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F);

    (g)☒ A parent holding company or control person in accordance with Sec. 240.13d-1(b)(1)(ii)(G);

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)☐ A non-U.S. institution in accordance with Sec. 240.13d-1(b)(1)(ii)(J);

    (k)☐ Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J). 

     

    Item 4. Ownership

     

    This statement is being filed with respect to an aggregate of 354,608 shares of Common Stock, resulting in beneficial ownership of Common Stock as follows:

     

    1.SilverArc

     

    (a)Amount Beneficially owned: 354,608.

     

    (b)Percent of Class: 6.60%.

     

    (c)Number of shares to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 354,608.

     

    (iii)Sole power to dispose or to direct the disposition of 0.

     

    (iv)Shared power to dispose or to direct the disposition of 354,608.

     

    2.Gandhi

     

    (d)Amount Beneficially owned: 354,608.

     

    (e)Percent of Class: 6.60%.

     

    (f)Number of shares to which the person has:

     

    (v)Sole power to vote or to direct the vote: 0.

     

    (vi)Shared power to vote or to direct the vote: 354,608.

     

    (vii)Sole power to dispose or to direct the disposition of: 0.

     

     

     

     

    CUSIP No.608550208 13G Page 6 of 9

     

    (viii)Shared power to dispose or to direct the disposition of: 354,608.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    ☐As of the date of this Report, the aggregate beneficial ownership of the Reporting Persons had been reduced to below five percent (5%).

     

    Item 6.Ownership of More than Five Percent on Behalf of another Person.

     

    SilverArc, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 354,608 shares, or 6.60% of the Common Stock believed to be outstanding, as a result of acting as investment adviser to various clients. Gandhi is the Sole Member of SilverArc and as such is deemed to be the beneficial owner of 354,608 shares, or 6.60% of the Common Stock believed to be outstanding.  Clients of SilverArc have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities. SilverArc Capital Alpha Fund I, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 14,110 of these 354,608 shares, which equates to 0.3% of the Common Stock believed to be outstanding. SilverArc Capital Alpha Fund II, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 250,896 of these 354,608 shares, which equates to 4.7% of the Common Stock believed to be outstanding. Squarepoint Diversified Partners Fund Limited, a Cayman Island exempted company for which SilverArc acts as investment adviser, may be deemed to beneficially own 89,602 of these 354,608 shares, which equates to 1.7% of the Common Stock believed to be outstanding.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable

     

     

     

     

    CUSIP No.608550208 13G Page 7 of 9

     

    Item 10.Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibits.  

    Exhibit A Joint Filing Agreement by and between the Reporting Persons dated February 14, 2024.

     

     

     

     

    CUSIP No.608550208 13G Page 8 of 9

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 14, 2024
      Date

     

    /s/ Devesh S. Gandhi 

     
    Devesh S. Gandhi, as Sole Member of SilverArc Capital Management, LLC  

     

    /s/ Devesh S. Gandhi 

     
    Devesh S. Gandhi  

     

     

     

      

    CUSIP No.608550208 13G Page 9 of 9

     

    EXHIBIT INDEX

     

    Ex.  
       
    A Joint Filing Agreement

     

     

    Get the next $MTEM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEM
    SEC Filings

    See more
    • SEC Form 8-K filed by Molecular Templates Inc.

      8-K - Molecular Templates, Inc. (0001183765) (Filer)

      1/2/25 4:13:52 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Molecular Templates Inc.

      8-K - Molecular Templates, Inc. (0001183765) (Filer)

      12/19/24 4:11:29 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Molecular Templates Inc.

      DEFA14A - Molecular Templates, Inc. (0001183765) (Filer)

      12/4/24 4:10:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

      AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of the Staff's determination pursuant to Nasdaq Listing Rule 5101 that the Company is a "public shell," and that, in the view of the Staff, the continued listing of the

      12/19/24 4:10:00 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

      AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced that it has received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on November 25, 2024. The notice indicated that MTEM is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of

      12/2/24 5:06:43 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/18/24 9:49:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/14/24 4:37:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/12/24 9:31:46 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Biotech Target N V sold $845,833 worth of shares (1,279,820 units at $0.66), closing all direct ownership in the company (SEC Form 4)

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      11/18/24 9:12:24 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lalande Kevin M.

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      9/30/24 5:41:36 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gruia Gabriela

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      9/30/24 5:37:40 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Leadership Updates

    Live Leadership Updates

    See more
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

      AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021. He was previously Global Program Head, Melanoma, at Novartis, a pos

      9/28/23 4:11:00 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Molecular Templates Strengthens Board of Directors and Management Team

      Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or "the Company"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel. "Dr. Gruia brings a wealth of industry knowledge to our Board of Directors," said Barry Selick, Ph.D., Chairman of the Board of Molecular

      3/2/22 8:00:00 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Biotech Target N V bought $587,500 worth of shares (250,000 units at $2.35), increasing direct ownership by 24% to 1,279,820 units (SEC Form 4)

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      4/4/24 8:13:35 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Molecular Templates with a new price target

      BofA Securities initiated coverage of Molecular Templates with a rating of Buy and set a new price target of $12.00

      4/21/21 6:52:47 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Molecular Templates with a new price target

      UBS initiated coverage of Molecular Templates with a rating of Neutral and set a new price target of $13.00

      2/1/21 7:51:02 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care